VectorBuilder and MaxCyte have partnered to develop a new gene delivery solution for clinical-grade cell engineering, integrating VectorBuilder’s MiniVec plasmid system with MaxCyte’s Flow Electroporation technology. This collaboration aims to address existing challenges in safety and manufacturability by offering a more efficient, safer, and scalable approach to ex vivo cell therapy development, benefiting from both companies' expertise in GMP-compliant solutions.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





